| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787537 | Journal of Thoracic Oncology | 2018 | 58 Pages |
Abstract
The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel. Atezolizumab continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Louis MD, Joachim MD, Keunchil MD, Achim MD, David R. MD, Santiago MD, Ji-Youn MD, Shirish M. MD, Toyoaki MD, Diego L. MD, Manuel MD, Dariusz M. MD, Filippo MD, Mayank MD, Bradford MS, Christina PhD, Marcin PhD, Pei PhD, Fabrice MD,